Skip to main content

Takeda Pharmaceutical Ltd ADR(TAK-N)
NYSE

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low16.56
Day High16.68
Open:16.60
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Tipranks
Takeda’s TAK-505 Trial Marks a New Bet on Difficult Solid Tumors
Tipranks
Takeda Targets Older Adults With New Dengue Vaccine Study, Eyeing Long-Term Market Upside
Tipranks
Takeda’s Real-World Dengue Vaccine Study Could Reshape Its Emerging Markets Outlook
Tipranks
Takeda Extends Pediatric Entyvio Data: What Long-Term Safety Tracking Means for TAK Investors
Tipranks
Takeda Updates Early-Stage Multiple Myeloma Study for TAK-079, Signaling Ongoing Oncology Push
Tipranks
Analysts Are Bullish on Top Healthcare Stocks: Allogene Therapeutics (ALLO), Takeda Pharmaceutical Company (TAK)
Tipranks
Takeda’s Long-Term Psoriatic Arthritis Trial Could Reshape TAK’s Immunology Outlook
Tipranks
Takeda’s Dual-Drug Crohn’s Study Could Reframe Entyvio’s Role in IBD Portfolios
Tipranks
Takeda Advances Dual-Therapy Ulcerative Colitis Study, Keeping Entyvio in the GI Spotlight
Tipranks
Takeda Tracks Real-World Safety of Alunbrig in Japanese Lung Cancer Patients
Tipranks
Takeda Deepens Real-World Evidence in Ultra-Rare cTTP With New ADAMTS13 Study
Tipranks
Takeda’s EXPLORHAE HAE Study in Egypt: Real‑World Data With Long‑Term Investor Upside
Tipranks
Takeda’s New South Korea HAE Study Aims to Cement Takhzyro’s Real World Edge
Tipranks
Takeda-Backed Phase 3 Lung Cancer Trial Pits Novel IBI363 Against Docetaxel
Tipranks
Takeda Maps Narcolepsy in Spain: What This New Epidemiology Study Means for Investors
Tipranks
Takeda Advances Fazirsiran Phase 3 Liver Study, Keeping Rare-Disease Growth Story in Play
Tipranks
Takeda’s TAK-861 Narcolepsy Study Moves Forward, Extending the Long-Term Bet on Sleep Disorders
Newswire.ca
Alan Walshe Appointed General Manager of Takeda Canada
Tipranks
Takeda Expands Fruquintinib Data With New Minority-Focused Colorectal Cancer Study
Tipranks
Takeda Tracks Real-World Safety of Fruzaqla in South Korean Colorectal Cancer Patients
Tipranks
Takeda’s Paediatric HAE Study Strengthens Real-World Case for Takhzyro
Tipranks
Takeda Expands Real-World Evidence for Takhzyro With New Saudi Arabia HAE Study
Newswire.ca
Next-Generation Psychiatric Therapies Target Massive $40B+ Market Opportunity
Tipranks
Takeda Advances Elritercept Into Phase 3, Targeting a New Edge in Anemia Care for MDS
Tipranks
Takeda’s Livmarli Safety Study in Japan: What Investors Should Watch in Rare Liver Disease
Tipranks
Takeda’s Cuvitru Safety Study: What a New Japanese Registry Update Means for TAK Investors
Tipranks
Takeda Targets Infection Risk in Multiple Myeloma With New Gammagard Phase 3 Study
Tipranks
Takeda Targets Better Hereditary Angioedema Diagnosis With New AHAE Study
Tipranks
Takeda’s HyQvia Study Tracks Real-World Use in Multiple Myeloma, Offering Gradual Upside for TAK Investors
Tipranks
Takeda’s New Stroke Trial Adds Long-Term Optionality to TAK’s Pipeline
Tipranks
Takeda Pushes Pediatric Psoriasis Drug TAK-279 Forward With New Phase 3 Trial Update
Tipranks
Takeda Advances Phase 3 Teen Depression Trial, Underscoring Its Neuroscience Strategy

Profile

Takeda Pharmaceutical Company Limited operates as a research-based pharmaceutical company, engaged in manufacturing, marketing, and importing/exporting pharmaceutical drugs. Takeda's core business comprise of ethical drugs and its portfolio includes lansoprazole for the treatment of peptic ulcers, leuprolide acetate for the treatment of prostate cancer and endometriosis, pioglitazone hydrocholoride for the treatment of diabetes, and candesartan cilexetil for the treatment of hypertension. The Company promotes enhancing R&D pipeline, while concentrating its management resources to the four core therapeutic areas: lifestyle-related diseases, oncology and urological diseases, central nervous system disease and gastroenterological diseases. It operates in two segments- Ethical drug business and Consumer healthcare business. Consumer healthcare business provides Alinamin (vitamin B1 derivative preparations, etc.), Benza (cold remedies). Takeda Pharmaceutical Company Limited is headquartered in Osaka, Japan.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.